Peptides by condition · Muscles, bones, joints and skin

Peptides studied for osteoporosis

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 15 study pages on osteoporosis: 15 in people (13 of them meta-analyses or randomized trials). They studied 3 compounds, with this many study pages each: Abaloparatide 8, Teriparatide 6 and MK-677 1.

What the research on osteoporosis looks like

Osteoporosis is bone that has grown thin and weak, so it breaks more easily, most often in the spine, the hip and the wrist. It is most common in women after menopause, and men get it too. Most bone drugs slow the breakdown of old bone; the two peptides studied here, teriparatide and abaloparatide, copy parathyroid hormone and a close relative of it, and push the body to build new bone instead.

Osteoporosis trials measure bone mineral density (BMD) on a DXA scan, a low-dose X-ray of the spine and hip, and count new fractures, above all new spine fractures seen on X-ray, against placebo or another bone drug. A few take a small core of bone from the hip to look at it under a microscope.

A gain in bone density on a scan is not the same as fewer broken bones, so the trials that counted fractures carry the most weight. Check what came after the peptide: these drugs are given for a set time and then usually followed by another bone drug, and several of these studies report the two in sequence.

Our study pages on osteoporosis by design: Trials in people 13, Other in people 2, Animals 0, Cells 0, of 15.Trials in people13Other in people2Animals0Cells0
How many of the 15 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.
A smiling woman with silver hair in a grey training top by a window, holding her phone

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The 15 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Abaloparatide

    8 in people

    For osteoporosis, 8 of our study pages are filed under Abaloparatide: 2 meta-analyses, 5 randomized trials and 1 clinical trial in people. The largest in people enrolled 2,463 people and was published in 2016. They were published from 2016 to 2025, in Front Endocrinol (Lausanne), J Orthop Surg Res, JAMA, J Bone Joint Surg Am, Arch Osteoporos, J Clin Endocrinol Metab, Bone and J Bone Miner Res.

    FDA-approved, with a use tied to osteoporosis on its label: Tymlos (injection) for osteoporosis at high risk of fracture in women after menopause, and building bone density in men with osteoporosis at high risk of fracture.

  2. Teriparatide

    6 in people

    For osteoporosis, 6 of our study pages are filed under Teriparatide: 1 meta-analysis, 4 randomized trials and 1 clinical trial in people. The largest in people pooled 6,680 people and was published in 2024. They were published from 2014 to 2024, in Arch Osteoporos, J Clin Endocrinol Metab, World Neurosurg and Lancet.

    FDA-approved, with a use tied to osteoporosis on its label: Forteo (injection) for osteoporosis at high risk of fracture in women after menopause and in men, and osteoporosis caused by long-term steroid treatment; Bonsity (injection) for osteoporosis at high risk of fracture in women after menopause and in men, and osteoporosis caused by long-term steroid treatment.

  3. MK-677

    1 in people

    For osteoporosis, 1 of our study pages is filed under MK-677: 1 randomized trial in people. It enrolled 292 people and was published in 2001, in J Clin Endocrinol Metab.

    MK-677 (ibutamoren) has no FDA-approved product: Drugs@FDA lists no application for it.

Side by side

For the 3 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Abaloparatide802,463Approved, a use tied to it
Teriparatide606,680Approved, a use tied to it
MK-67710292Not approved

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for osteoporosis?

Our 15 study pages on osteoporosis are filed under 3 compounds, with this many each: Abaloparatide 8, Teriparatide 6 and MK-677 1. Abaloparatide has the most.

Have any been tested in people with osteoporosis?

Yes: all 15 were in people, 13 of them meta-analyses or randomized trials (Abaloparatide, Teriparatide and MK-677). The largest pooled 6,680 people: “Teriparatide cut fracture risk vs bisphosphonates (RR 0.61)” (2024).

Is any peptide FDA-approved for osteoporosis?

Yes, with a use tied to osteoporosis on their FDA labels: Abaloparatide as Tymlos; Teriparatide as Forteo and Bonsity. 1 other compound here with an FDA record has no use tied to it.

How large were the studies in people on osteoporosis?

Of the 15 in people, 9 give their size on our pages: 2 had 1,000 people or more, 2 had 100 to 999 and 5 had fewer than 100. The largest, a meta-analysis from 2024, pooled 6,680.

What is the newest study on osteoporosis here?

Of our study pages on osteoporosis, the newest is “Abaloparatide, teriparatide beat other drugs on spine BMD in men”, a meta-analysis in people published in 2025.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

Track it in the app

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo